Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 10 result(s).

Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing

Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of a full range of natural healthcare products, and innovative mental health treatment, is pleased to announce a product listing agreement for a range of Havn Life's natural health products,…

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased to announce it has signed a…

Havn Life Announces Launch of a Range of Natural Health Products

Havn Life Sciences Inc. (CNSX:HAVN) (FRA:5NP), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce its initial seven natural health supplements. These 7 products will be Havn Life's first natural health products to launch…

HAVN Life Sciences Has Been One Of The Best Performing Stocks In The Psychedelics Sector Over The Past Month

Last month, Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) commenced trading on the Canadian Stock Exchange (CSE) and is an opportunity that we have been closely following. We consider Havn Life to be an attractive play on the burgeoning psychedelic therapy market and believe that the opportunity is flying under the…

Havn Life Sciences Signs Agreement to Supply Psychedelic Compounds for use in Research and Development to Revive Therapeutics

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has signed an agreement to supply Revive Therapeutics Ltd. (CSE:RVV, USA:RVVTF) with psychedelic compounds for use in investigational new drug…

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served…

Havn Life joins UK Psychedelics Working Group with Leading International Scientists

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has joined the Drug Science Medical Psychedelics Working Group consortium. The working group was…

HAVN Life Sciences Is Off To A Great Start Out Of The Gate

Last week, Havn Life Sciences Inc. (CSE:HAVN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol HAVN. The biotech company has been focused on the development of standardized psychoactive compounds that are derived from plants and fungi for use in research and is an opportunity that we…

Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE

Havn Life Sciences Inc. (CSE:HAVN), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has commenced trading on the Canadian Securities Exchange ("CSE") under the ticker symbol "HAVN". "Listing on the Canadian…

HAVN Life Sciences Continues To Execute On Growth Initiatives Ahead Of Its Upcoming Public Listing

We have seen a substantial increase in interest in psychedelic focused businesses during the last month and this is a trend that our readers need to be aware of. The psychedelic sector has recently come under pressure and we encourage our readers to conduct significant due diligence on companies in…

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link